ANP on track to be the next SRPT ? Now they can start the MS trial too after ATL1102 showing positiv eeffect at lower dose .STRONG BUY
“I joined the board of Sarepta in 2007. We were in a very similar circumstance as Antisense,” he told *.
“We had a low market cap, we had low cash balance, we were fighting to get to the point where we could prove out our drug. Now look at what’s changed in the last 10 years. That’s what we’re trying to achieve at Antisense.”
DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-270
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
